Advertisement

Targeted Therapies for Lung Cancer

  • Ravi Salgia
Book

Part of the Current Cancer Research book series (CUCR)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Zorawar S. Noor, Jonathan W. Goldman
    Pages 1-30
  3. Nicolas A. Villanueva, Nicholas P. Giustini, Lyudmila A. Bazhenova
    Pages 31-54
  4. Leslie G. Oesterich, Jonathan W. Riess
    Pages 55-78
  5. Nathaniel J. Myall, Sukhmani K. Padda
    Pages 79-100
  6. Ajaz Bulbul, Alessandro Leal, Hatim Husain
    Pages 125-136
  7. Xiaoliang Wu, Lin Zhu, Patrick C. Ma
    Pages 137-161
  8. Marianna Koczywas, Idoroenyi Amanam
    Pages 163-178
  9. Colt A. Egelston, Peter P. Lee
    Pages 179-194
  10. Arnab Basu, Jorge Nieva
    Pages 195-216
  11. Back Matter
    Pages 233-238

About this book

Introduction

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

Keywords

lung cancer targeted therapy tyrosine kinase inhibitors immunotherapy combination therapies immune checkpoint blockade

Editors and affiliations

  • Ravi Salgia
    • 1
  1. 1.Department of Medical Oncology and Therapeutics ResearchCity of Hope National Medical CenterDuarteUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-030-17832-1
  • Copyright Information Springer Nature Switzerland AG 2019
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-030-17831-4
  • Online ISBN 978-3-030-17832-1
  • Series Print ISSN 2199-2584
  • Series Online ISSN 2199-2592
  • Buy this book on publisher's site